| __timestamp | Sarepta Therapeutics, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 49315000 | 1499100000 |
| Thursday, January 1, 2015 | 75043000 | 1923500000 |
| Friday, January 1, 2016 | 83749000 | 2351400000 |
| Sunday, January 1, 2017 | 122682000 | 2564000000 |
| Monday, January 1, 2018 | 207761000 | 2397300000 |
| Tuesday, January 1, 2019 | 284812000 | 2503400000 |
| Wednesday, January 1, 2020 | 317875000 | 3344600000 |
| Friday, January 1, 2021 | 282660000 | 4529200000 |
| Saturday, January 1, 2022 | 451421000 | 4179100000 |
| Sunday, January 1, 2023 | 481871000 | 4650100000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of key players is crucial. Over the past decade, Viatris Inc. and Sarepta Therapeutics, Inc. have demonstrated distinct approaches to their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Viatris Inc. consistently outspent Sarepta Therapeutics, with SG&A expenses peaking at approximately $4.65 billion in 2023, a staggering 210% increase from 2014. In contrast, Sarepta's SG&A expenses grew by nearly 880% over the same period, reaching around $482 million in 2023. This divergence highlights Viatris's expansive operational scale compared to Sarepta's focused growth strategy. As the pharmaceutical industry continues to innovate, these spending patterns offer insights into each company's strategic priorities and market positioning.
Breaking Down SG&A Expenses: Zoetis Inc. vs Viatris Inc.
Who Optimizes SG&A Costs Better? Zoetis Inc. or Sarepta Therapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc. vs Walgreens Boots Alliance, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Sarepta Therapeutics, Inc. or Evotec SE